Curevac N V Revenue Growth Rates (CVAC), Current and Historic Growth - CSIMarket
CSIMarket
 


Curevac N v   (NASDAQ: CVAC)
 

CVAC's Revenue Growth by Quarter and Year

Curevac N V 's Revenue results by quarter and year




CVAC Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.41
1st Quarter March 0.94
FY 2.35





CVAC Revenue second quarter 2025 Y/Y Growth Comment
Curevac N V reported drop in Revenue in the second quarter 2025 by -90.92% to $ 1.41 millions, from the same quarter in 2024.
The fall in the second quarter 2025 Curevac N V 's Revenue compares unfavorably to the Company's average Revenue doubling of 303.36%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Revenue growth. While Curevac N V ' s Revenue meltdown of -90.92% ranks overall at the positon no. 596 in the second quarter 2025.




CVAC Revenue ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December - 895.52 % 404.27 % -1.24 %
3rd Quarter September - 2924.75 % 58.9 % -79.38 %
2nd Quarter June -90.92 % 88.36 % -61.56 % -
1st Quarter March -93 % 75.56 % -72.02 % -
FY   - 1145.09 % 30.57 % -

Financial Statements
Curevac N V 's second quarter 2025 Revenue $ 1.41 millions CVAC's Income Statement
Curevac N V 's second quarter 2024 Revenue $ 15.54 millions Quarterly CVAC's Income Statement


CVAC Revenue (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - 10.46 % 235.62 % 5.76 %
3rd Quarter September - 3391.89 % 117.45 % -47.39 %
2nd Quarter June 50.1 % 15.71 % 7.84 % -21.51 %
1st Quarter March -99.84 % -77.69 % -35.93 % 126.14 %
FY (Year on Year)   - 1145.09 % 30.57 % -




Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #149
Overall #596

Revenue Y/Y Growth Statistics
High Average Low
895.54 % 303.36 % -15.23 %
(Dec 31 2024)   (Dec 31 2023)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #149
Overall #596
Revenue Y/Y Growth Statistics
High Average Low
895.54 % 303.36 % -15.23 %
(Dec 31 2024)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Curevac N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3391.52 % 248.16 % -99.84 %
0  


CVAC's II. Quarter Q/Q Revenue Comment
Curevac N v achieved in the II. Quarter 2025 below company average Revenue jump of 50.1% quarter on quarter, to $ 1.41 millions.

II. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.71% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Curevac N V 's Revenue growth quarter on quarter, overall rank is 408.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #93
Overall #408
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #93
Overall #408
Revenue Q/Q Growth Statistics
High Average Low
3391.52 % 248.16 % -99.84 %
0  


CVAC's II. Quarter Q/Q Revenue Comment
Curevac N v achieved in the II. Quarter 2025 below company average Revenue jump of 50.1% quarter on quarter, to $ 1.41 millions.

II. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.71% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Curevac N V 's Revenue growth quarter on quarter, overall rank is 408.


Curevac N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
12 Months Ending
Cumulative Revenue 12 Months Ending $ 599.40 $ 60.21 $ 71.02 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 895.54 % -15.23 % 29.76 % - -
Year on Year Revenue Growth Overall Ranking # 596 # 1197 # 1084 # 0 # 0
Seqeuential Revenue Change (TTM) 895.54 % -15.23 % 29.76 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 596 # 1197 # 1084 # 0 # 0


Cumulative Revenue growth Comment
With 895.54% annual Revenue growth, Curevac N V would report a record annual Revenue surge if the fiscal year would end on Dec 31 2024.

In the Healthcare sector 148 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 596, from total ranking in previous quarter at 1197.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 149
Overall # 596

Revenue TTM Y/Y Growth Statistics
High Average Low
895.54 %
303.36 %
-15.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 149
S&P 500 # 596
Cumulative Revenue growth Comment
With 895.54% annual Revenue growth, Curevac N V would report a record annual Revenue surge if the fiscal year would end on Dec 31 2024.

In the Healthcare sector 148 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 596, from total ranking in previous quarter at 1197.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 149
Overall # 596

Revenue TTM Y/Y Growth Statistics
High Average Low
895.54 %
303.36 %
-15.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 149
S&P 500 # 596




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CVAC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Carlisle Companies Incorporated-0.08%$ -0.076 millions
Zimvie Inc -0.13%$ -0.128 millions
Community Health Systems Inc -0.22%$ -0.223 millions
Bruker Corporation-0.46%$ -0.462 millions
Integra Lifesciences Holdings Corp-0.61%$ -0.615 millions
Adapthealth Corp -0.70%$ -0.695 millions
Perrigo Company Plc-0.79%$ -0.789 millions
Organon and Co -0.81%$ -0.809 millions
Castle Biosciences Inc -0.94%$ -0.936 millions
Vaso Corporation-0.96%$ -0.963 millions
Profound Medical Corp -0.99%$ -0.985 millions
Capsovision Inc -1.13%$ -1.126 millions
Avantor Inc -1.14%$ -1.139 millions
Inspiremd Inc -1.35%$ -1.352 millions
Align Technology inc -1.51%$ -1.509 millions
Teladoc Health Inc -1.64%$ -1.641 millions
Supernus Pharmaceuticals inc -1.71%$ -1.706 millions
Encision Inc -1.73%$ -1.729 millions
Cytek Biosciences Inc -1.80%$ -1.796 millions
Merck and Co Inc -1.90%$ -1.899 millions
Bioventus Inc -1.98%$ -1.978 millions
Alkermes Plc -2.12%$ -2.123 millions
Anteris Technologies Global Corp -2.22%$ -2.215 millions
Surmodics Inc -2.55%$ -2.551 millions
Nrc Health-2.81%$ -2.807 millions
Rxsight Inc -3.09%$ -3.095 millions
Apyx Medical Corp-3.57%$ -3.567 millions
Quidelortho Corp-3.63%$ -3.626 millions
Lantheus Holdings Inc -4.00%$ -4.003 millions
Quipt Home Medical Corp -4.07%$ -4.065 millions


About Curevac N V Revenue Growth Rates (CVAC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Curevac N v (CIK 1809122).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410578-25-000692
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Curevac N v ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.